
HMX Short Course

Advances in Immunological Therapeutics - Vol. 1 (2023)

Learn about innovative immunological therapies approved by the FDA from 2021 through 2023 for the treatment of a number of chronic diseases.

Over the past few decades, it has become increasingly clear that a weakened or overactive immune response underlies the development of many chronic conditions, ranging from autoimmune diseases to cancer. Advances in our understanding of our immune system has led to the development of therapies that modulate immune responses to treat various conditions with an immunological basis. Learning how new therapies enhance or suppress our immune system is essential for anyone looking to develop or apply new immunomodulatory therapies to treat disease.

This course offers a unique way for professionals to learn from leading Harvard Medical School faculty about cutting-edge immunological therapeutics that have been recently approved by the FDA for the treatment of a number of different chronic diseases.

Topics Covered

Advances in Immunological Therapeutics - Vol. 1 (2023)

- Treating Skin Inflammation
- Lymphocyte Depletion
- Immune Checkpoint Blockade
- Complement Inhibition
- Reducing the Half-Life of IgG
- Blocking Type I Interferons
- Blocking Other Kinases

HMX Short Courses feature targeted lessons on the latest medical science information and advancements to keep learners up to date.